Incidence, trends, and predictors of ischemic stroke 30 days after an acute myocardial infarction

Stroke

Volumn 45, Issue 5, 2014, Pages 1324-1330

  Kajermo, Ulf ^a   Ulvenstam, Anders ^b   Modica, Angelo ^b   Jernberg, Tomas ^c   Mooe, Thomas ^d  

^a SKARABORG HOSPITAL   (Sweden)

^b ÖSTERSUND HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Epidemiology; Myocardial infarction; Risk factors; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; AGE; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; EVENT FREE SURVIVAL; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EPIDEMIOLOGY; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; STROKE; SWEDEN; TIME FACTORS;

EID: 84899966599     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001963     Document Type: Article

References (33)

1. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B; CDBE2010 Study Group; European Brain Council. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155-162.
2. Tanne D, Gottlieb S, Hod H, Reicher-Reiss H, Boyko V, Behar S. Incidence and mortality from early stroke associated with acute myocardial infarction in the prethrombolytic and thrombolytic eras. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) and Israeli Thrombolytic Survey Groups. J Am Coll Cardiol. 1997;30:1484-1490.
3. Saczynski JS, Spencer FA, Gore JM, Gurwitz JH, Yarzebski J, Lessard D, et al. Twenty-year trends in the incidence of stroke complicating acute myocardial infarction: Worcester Heart Attack Study. Arch Intern Med. 2008;168:2104-2110.
4. Wienbergen H, Schiele R, Gitt AK, Schneider S, Heer T, Gottwik M, et al. Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice. MIR and MITRA Study Groups. Myocardial Infarction Registry. Maximal Individual Therapy in Acute Myocardial Infarction. Am J Cardiol. 2001;87:782-785, A788.
5. Elkind MSV, Sacco RL. Pathogenesis, classification, and epidemiology of cerebrovascular disease. In: Rowland LP, Pedley TA, eds. Merritt's Neurology. Philadelphia, PA: Lippincott Williams and Wilkins; 2009: 250-263.
6. Falk E, Shah PK, Fuster V. Atherothrombosis and thrombosis-prone plaques. In: Fuster V, Alexander RW, O'Rourke RA, eds. Hurst's the Heart. Philadelphia, PA: McGraw-Hill Medical; 2004: 1123-1140.
7. Ridker PM, Libby P. Risk factors for atherothrombotic disease. In: Libby P, Bonow RO, Mann DL, Zipes DP, eds. Braunwald's Heart Disease. Philadelphia, PA: Saunders Elsevier; 2008: 1003-1026.
8. Witt BJ, Ballman KV, Brown RD Jr, Meverden RA, Jacobsen SJ, Roger VL. The incidence of stroke after myocardial infarction: a meta-analysis. Am J Med. 2006;119:354.e1-e354.e9.
9. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Yawn BP, Roger VL. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med. 2005;143:785-792.
10. Stenestrand U, Wallentin L; Swedish Register of Cardiac Intensive Care. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430-436.
11. Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, et al. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617-1621.
12. Janszky I, Ahnve S, Ljung R, Mukamal KJ, Gautam S, Wallentin L, et al. Daylight saving time shifts and incidence of acute myocardial infarction- Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Sleep Med. 2012;13:237-242.
13. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
16. Mooe T, Eriksson P, Stegmayr B. Ischemic stroke after acute myocardial infarction. A population-based study. Stroke. 1997;28:762-767.
17. Budaj A, Flasinska K, Gore JM, Anderson FA, Dabbous OH, Spencer FA, et al. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes. Circulation. 2005;111:3242-3247.
18. Dacey LJ, Likosky DS, Leavitt BJ, Lahey SJ, Quinn RD, Hernandez F Jr, et al; Northern New England Cardiovascular Disease Study Group. Perioperative stroke and long-term survival after coronary bypass graft surgery. Ann Thorac Surg. 2005;79:532-536, discussion 537.
19. Selnes OA, Gottesman RF, Grega MA, Baumgartner WA, Zeger SL, McKhann GM. Cognitive and neurologic outcomes after coronary-artery bypass surgery. N Engl J Med. 2012;366:250-257.
20. Tanne D, Reicher-Reiss H, Boyko V, Behar S. Stroke risk after anterior wall acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. Am J Cardiol. 1995;76:825-826.
21. Thompson PL, Robinson JS. Stroke after acute myocardial infarction: relation to infarct size. Br Med J. 1978;2:457-459.
22. Fonseca C, Morais H, Mota T, Matias F, Costa C, Gouveia-Oliveira A, et al. The diagnosis of heart failure in primary care: value of symptoms and signs. Eur J Heart Fail. 2004;6:795-800, 821-792.
23. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-q-wave myocardial infarction. Circulation. 2002;106:1690-1695
24. Van De Graaff E, Dutta M, Das P, Shry EA, Frederick PD, Blaney M, et al. Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction. Stroke. 2006;37:2546-2551.
25. ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349-360.
26. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251.
27. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
28. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. JAMA. 2005;294:1224-1232.
29. Chen Z, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621.
30. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1990;336:65-71.
31. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet. 1992;339:753-770.
32. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30:962-969.
33. Swedeheart annual report 2011. 2012. http://www.ucr.uu.se/swedeheart/ index.php/arsrapporter/doc-download/178-swedeheart-annual-report- 2011-english. Accessed January 26, 2014.